EGFR and glioblastoma: Shikonin and its derivatives suppress the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib, possibly being a potential strategy to overcome drug resistance to erlotinib (Zhao et al., 2015).